Survodutide
Dual GLP-1/Glucagon Receptor Agonist · Weight Loss & Diabetes
Investigational dual receptor agonist targeting metabolic disease through balanced GLP-1R and GCGR activation. Phase 2/3 clinical trials demonstrate superior weight loss and MASH treatment efficacy.
Overview
Investigational dual receptor agonist targeting metabolic disease through balanced GLP-1R and GCGR activation. Phase 2/3 clinical trials demonstrate superior weight loss and MASH treatment efficacy.
Dual agonism: GLP-1R reduces appetite and slows gastric emptying; GCGR increases energy expenditure and hepatic fat oxidation. EC50 0.52nM GCGR, 0.33nM GLP-1R.
Research indications
What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.
14.9% mean weight loss at 46 weeks (4.8mg); 55% achieved ≥15% reduction.
Superior to semaglutide: -8.7% vs -5.3% at 16 weeks.
Dual mechanism addresses both energy intake and expenditure.
62% achieved MASH improvement without fibrosis worsening at 4.8mg.
63-67% achieved ≥30% liver fat reduction.
HbA1c reduction up to -1.6% at highest doses.
A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.
- Class
- Peptide with fatty acid acylation
- Chain length
- 29 residues
- Molecular weight
- 4500 Da
- Half-life
- ~112 h
- Typical dose
- 0.6mg starting, titrate up to 3.6-6.0mg weekly
- Frequency
- Once weekly (same day each week)
- Cycle length
- 24-76+ weeks continuous therapy
- Storage
- Reconstituted: 2-8°C immediately after mixing
Molecular data
- Type
- Peptide with fatty acid acylation
- Molecular weight
- 4500 Da
- Chain length
- 29 residues
- Half-life
- 6720 min
Dosing reference
Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.
| Context | Route | Amount | Frequency |
|---|---|---|---|
| Obesity - Conservative Start | SubQ | 0.6mg titrated over 24 weeks | Once weekly with 4-week intervals |
| Obesity - Standard Protocol | SubQ | 3.6-6.0mg | Once weekly |
| MASH Treatment | SubQ | 2.4-4.8mg | Once weekly |
| Type 2 Diabetes | SubQ | 0.3-2.7mg | Once weekly |
Interactions
Both GLP-1 agonists; combining risks excessive activation and GI side effects.
Demonstrated together in Phase 2 diabetes trials.
No known interactions; allowed in Phase 3 with monitoring.
Hypoglycemia risk; consider dose reduction.
May require insulin dose reduction due to improved glycemic control.
Take 1+ hour before survodutide due to delayed gastric emptying.
Risk of excessive glucagon receptor activation.
Quality checklist
- ✓Clear to slightly opalescent solution without visible particles
- ✓Sealed vial with intact rubber stopper
- ✓Within expiration date
- !Slight foam after reconstitution is normal if disappears within minutes
- ×Cloudy solution or visible particles indicates contamination
- ×Discoloration of powder or solution
What to expect
Safety
- Nausea (40-66%)
- Diarrhea (25-49%)
- Vomiting (15-41%)
- Slight heart rate increase (mean 2-5 bpm)
- Severe persistent nausea/vomiting preventing oral intake
- Signs of pancreatitis (severe abdominal pain radiating to back)
- Allergic reactions (rash, itching, difficulty breathing)
- Severe hypoglycemia with insulin/sulfonylureas
- Gallbladder symptoms (right upper quadrant pain)
- Significant tachycardia or arrhythmias
- Not recommended in pregnancy or breastfeeding
- Use contraception during treatment
FAQ
Why is survodutide superior to semaglutide for weight loss?
Survodutide adds glucagon receptor agonism to GLP-1 effects, creating dual appetite suppression and energy expenditure increase. Head-to-head trials show -8.7% weight loss vs semaglutide's -5.3% at 16 weeks, because the glucagon pathway enhances fat burning independent of appetite.
Can survodutide reverse MASH (metabolic dysfunction-associated steatohepatitis)?
Yes, clinical trials show 62% of MASH patients achieved improvement without fibrosis worsening at 4.8mg weekly, with 63-67% achieving ≥30% liver fat reduction. This makes it one of the first investigational agents with FDA potential for both MASH treatment and weight loss.
Is survodutide's 6-day half-life long enough for once-weekly dosing?
Yes, the ~6-day half-life allows effective once-weekly dosing because peak levels remain therapeutic throughout the week. This contrasts with semaglutide (7-day half-life) - survodutide's slightly shorter half-life still covers the weekly interval adequately.
Does survodutide cause heart rate increases like other GLP-1 drugs?
Survodutide shows a mean 2-5 bpm heart rate increase, similar to semaglutide. The glucagon receptor activation is modest enough to avoid significant tachycardia, though patients with cardiac conditions should monitor closely as with all GLP-1 agonists.